multiple myeloma | pharmaphorum

Friday 22 May 2026

multiple myeloma

News

J&J sign (Wikimedia Commons)

Straight after its first cancer bispecific OK, J&J highlight...

With the ink barely dry on the FDA's approval of Johnson & Johnson's Rybrevant, its first bispecific antibody for cancer, the drugmaker is already showcasing others in its pipeline.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen files its first CAR-T therapy cilta-cel in Europe

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

News

Sanofi Headquarters in Paris

Sanofi's Sarclisa gains new US multiple myeloma indication

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year.

News

BMS_sign

FDA approves BMS' multiple myeloma CAR-T Abecma

The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease.

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

NICE backs ovarian cancer and multiple myeloma combination d...

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma.

Events

Partner Content

BCMA Targeted Therapies Summit

Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused